Clinical Trials Directory

Trials / Completed

CompletedNCT02518737

Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity

Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide

Status
Completed
Phase
Study type
Observational
Enrollment
36 (actual)
Sponsor
University of Copenhagen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The bone tissue of the human adult body is in a constant process of break-down (resorption) and rebuilding (formation), a process called bone remodeling. The extent to which bone remodeling happens varies during the day, especially a decrease in the bone resorption is observed after eating. The overall purpose of this study is to examine the possible role of the hormone Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from cells in the gut after eating, and previous studies have shown an effect of GIP on bone tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in women with a mutation in the GIP receptor, when compared to women with a normal functioning GIP receptor. In the present study humans with a mutation in their GIP receptor is compared to humans with a normal functioning GIP receptor. The study population will be examined during a meal stimulation test, where blood will be sampled regularly. The blood samples will be examined for markers of bone resorption among other markers of bone remodeling, GIP and other gut hormones. The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone resorption. Thus it is expected that the decrease in resorption is less pronounced in the humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP receptor.

Conditions

Interventions

TypeNameDescription
OTHERMeal Test

Timeline

Start date
2015-09-01
Primary completion
2016-06-01
Completion
2016-06-01
First posted
2015-08-10
Last updated
2016-07-29

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02518737. Inclusion in this directory is not an endorsement.